Tea substitute drink for preventing and treating hyperuricemia

Abstract

The invention discloses a tea substitute drink for preventing and treating hyperuricemia. The tea substitute drink comprises the following raw materials: codonopsis pilosula, bighead atractylodes rhizome, rhizoma atractylodis, poria cocos, rhizoma smilacis glabrae, honeysuckle, edible tulip, salvia miltiorrhiza, gynostemma pentaphylla and the like. The traditional Chinese medicine composition has the effects of replenishing qi to invigorate the spleen, clearing damp and reducing phlegm, clearing away heat and toxic materials, removing blood stasis and promoting coronary circulation, effectively prevents and treats hyperuricemia, and reduces hyperuricemia complicated with cardiovascular and cerebrovascular diseases. The blood uric acid and triglyceride levels of patients can be effectively reduced, the blood fat can be reduced, and the morbidity of hyperuricemia accompanied by cardiovascular and cerebrovascular diseases can be reduced. The traditional Chinese medicine composition is prepared from various Chinese herbal medicine raw materials, has small side effects on a human body, is low in preparation cost and can be widely applied to treatment of hyperuricemia.

Description

Technical Field

[0001] The invention relates to the technical field of traditional Chinese medicines, in particular to a tea substitute for preventing and treating hyperuricemia. Background Art

[0002] Hyperuricemia is a chronic metabolic disease mainly caused by purine metabolism disorder, often accompanied by many cardiovascular and cerebrovascular diseases such as hypertension, heart failure, arteriosclerosis and coronary heart disease. Clinically, it is often manifested as a continuous increase in human blood uric acid levels. With the acceleration of global aging and changes in living and eating habits, the incidence of hyperuricemia is on the rise worldwide. At present, the incidence of hyperuricemia in my country has reached 20% in men over 40 years old. Hyperuricemia and gout, like obesity, diabetes, cardiovascular disease and tumors, are collectively referred to as non-communicable diseases and have become the number one health threat in my country.

[0003] In the existing technology, Western medicine mainly uses uric acid-lowering drugs, such as allopurinol and benzbromarone, to treat hyperuricemia. Although these drugs can reduce blood uric acid levels, long-term use may cause side effects such as liver and kidney damage and skin rashes. Hyperuricemia patients are concerned about the side effects of long-term use of Western medicine. Summary of the invention

[0004] The purpose of the present invention is to overcome the above problems and provide a tea substitute for preventing and treating hyperuricemia. To achieve the above purpose, the present invention adopts the following technical solutions:

[0005] A tea substitute for preventing and treating hyperuricemia, comprising the following ingredients:

[0006] 8-12 parts of Codonopsis pilosula, 8-12 parts of Atractylodes macrocephala, 8-12 parts of Atractylodes lancea, 8-12 parts of Poria or Polyporus, 8-12 parts of Smilax glabra, 8-12 parts of Honeysuckle, 8-12 parts of Trillium, 8-12 parts of Salvia miltiorrhiza, 8-12 parts of Gynostemma pentaphyllum, 4-8 parts of Rhodiola rosea, 4-8 parts of Alismatis orientalis, and 4-8 parts of Licorice.

[0007] As an improvement, the raw materials include the following ingredients: 10 parts of Codonopsis pilosula, 10 parts of Atractylodes macrocephala, 10 parts of Atractylodes lancea, 10 parts of Poria cocos or Polyporus umbellatus, 10 parts of Smilax glabra, 10 parts of Honeysuckle, 10 parts of Trillium gracile, 10 parts of Salvia miltiorrhiza, 10 parts of Gynostemma pentaphyllum, 6 parts of Rhodiola rosea, 6 parts of Alisma orientalis, and 6 parts of Licorice.

[0008] The advantages of the present invention are:

[0009] 1. The main cause of hyperuricemia is that uric acid is generated too much or discharged too little in the body, so increasing uric acid excretion is the key to treating the disease. The present invention has significant efficacy in invigorating qi and strengthening spleen, removing dampness and resolving phlegm, clearing away heat and detoxicating, and removing blood stasis and dredging meridians to treat hyperuricemia. In the prescription, Codonopsis pilosula, Atractylodes macrocephala, Atractylodes lancea, Poria cocos, Smilax glabra, and Licorice are used to invigorate spleen and invigorate qi, remove dampness and resolve phlegm, honeysuckle and Tripterygium wilfordii are used to clear away heat and detoxicating, and Salvia miltiorrhiza, Rhodiola rosea, and Gynostemma pentaphyllum are used to invigorate qi, promote blood circulation and dredge meridians; Alisma orientalis is used to infiltrate dampness and promote diuresis, and plays the functions of invigorating qi and strengthening spleen, removing dampness and resolving phlegm, clearing away heat and detoxicating, and removing blood stasis and dredge meridians. All medicines complement each other, so that spleen and kidney deficiency can be supplemented, phlegm and dampness can be removed, heat can be retreated, blood stasis can be promoted, and turbid evil can be discharged, providing a new treatment strategy for the treatment of hyperuricemia.

[0010] 2. The present invention can effectively reduce the patient's blood uric acid and triglyceride levels, lower blood lipids, and reduce the incidence of cardiovascular and cerebrovascular diseases associated with hyperuricemia.

[0011] 3. The present invention adopts a variety of Chinese herbal medicine raw materials, has little side effects on the body, is low in harm, has a low production cost, and can be widely used in the treatment of hyperuricemia. DETAILED DESCRIPTION

[0012] The present invention is described in detail and specifically by specific examples below to provide a better understanding of the present invention, but the following examples do not limit the protection scope of the present invention.

[0013] Example 1

[0014] This embodiment discloses a tea substitute for preventing and treating hyperuricemia, the raw materials of which include the following ingredients:

[0015] Codonopsis pilosula 8g, Atractylodes macrocephala 8g, Poria 8g, Smilax glabra 8g, Honeysuckle 8g, Trillium 8g, Salvia miltiorrhiza 8g, Gynostemma pentaphyllum 8g, Rhodiola rosea 4g, Alisma orientalis 4g, and Licorice 4g.

[0016] The preparation and use method of the invention is as follows: various raw materials are mixed in proportion, and then 2000 ml of water is added for decoction.

[0017] Example 2

[0018] This embodiment discloses a tea substitute for preventing and treating hyperuricemia.

[0019] The raw materials include the following ingredients:

[0020] Codonopsis pilosula 10g, Atractylodes macrocephala 10g, Atractylodes lancea 10g, Poria 10g, Smilax glabra 10g, Honeysuckle 10g, Trillium 10g, Salvia miltiorrhiza 10g, Gynostemma pentaphyllum 10g, Rhodiola rosea 6g, Alisma orientalis 6g, and Licorice 6g.

[0021] The preparation and use method of the invention is as follows: various raw materials are mixed in proportion, and then 2000 ml of water is added for decoction.

[0022] Example 3

[0023] This embodiment discloses a tea substitute for preventing and treating hyperuricemia.

[0024] The raw materials include the following ingredients:

[0025] Codonopsis pilosula 10g, Atractylodes macrocephala 10g, Poria 10g, Smilax glabra 10g, Honeysuckle 10g, Trillium 10g, Salvia miltiorrhiza 10g, Gynostemma pentaphyllum 10g, Rhodiola rosea 6g, Alisma orientalis 6g, Licorice root 6g, Polyporus 10g.

[0026] The preparation and use method of the invention is as follows: various raw materials are mixed in proportion, and then 2000 ml of water is added for decoction.

[0027] Research subjects and methods

[0028] 1.1 Research subjects A total of 200 patients diagnosed with hyperuricemia were selected from the physical examination clients of the physical examination center from December 2017 to November 2019 and were divided into a control group (100 cases) and a treatment group (100 cases) according to the random number table method. There were 68 males and 32 females in the control group; the age ranged from 42 to 59 years old, with an average age of (51.23±3.91) years old; 31 cases of hypertension, 29 cases of coronary heart disease, 27 cases of arteriosclerosis, and 13 cases of heart failure. There were 69 males and 31 females in the treatment group; the age ranged from 43 to 58 years old, with an average age of (51.72±3.88) years old; 33 cases of hypertension, 28 cases of coronary heart disease, 28 cases of arteriosclerosis, and 11 cases of heart failure. There was no statistically significant difference in the data between the two groups (P>0.05).

[0029] 1.1.1 Diagnostic criteria The diagnostic criteria for hyperuricemia are based on the Journal of Internal Medicine: Under normal purine diet, serum uric acid levels in men and postmenopausal women are >420 μmol / L, and those in premenopausal women are >360 μmol / L.

[0030] 1.1.2 Inclusion criteria ① Approved by the ethics committee; ② The patient signed the informed consent form; ③ Meet the above diagnostic criteria; ④ Hyperuricemia combined with other cardiovascular and cerebrovascular diseases.

[0031] 1.1.3 Exclusion criteria: ① Those who are allergic to the drugs used; ② Those with severe primary diseases such as liver, kidney and hematopoietic system; ③ Those with mental disorders and unable to cooperate with treatment; ④ Those under 15 years old and over 75 years old, pregnant or lactating women.

[0032] 1.2 Research Methods All patients who met the criteria were screened and enrolled in the study and were given a low-purine diet and were required to drink plenty of water, with the amount of water consumed being no less than 2000 mL.

[0033] Control group: Oral administration of benzbromarone capsules, 50 mg / time, once / d, for 4 consecutive weeks, taken with breakfast; 4 weeks was one course of treatment, and 1 course of treatment was given in total.

[0034] Treatment group: Orally take benzbromarone tablets, and take the tea substitute of the present invention: 10g of Codonopsis pilosula, 10g of Atractylodes macrocephala, 10g of Atractylodes lancea, 10g of Poria, 10g of Smilax glabra, 6g of Licorice, 10g of Honeysuckle, 10g of Trillium, 10g of Salvia miltiorrhiza, 10g of Rhodiola rosea, 10g of Gynostemma pentaphyllum, and 6g of Alismatis, decocted in water for 2000mL of tea substitute, 4 weeks as one course of treatment, and a total of one course of treatment.

[0035] 1.3 Observation indicators and efficacy judgment criteria

[0036] 1.3.1 Observation indicators 8 mL of fasting blood was drawn from the patient in the morning and centrifuged at 3000 r / min for 5 min. The upper serum was taken and placed in a -80°C refrigerator for testing. The blood uric acid (UA) and triglyceride (TG) levels of the patient were tested before and after treatment.

[0037] 1.3.2 Efficacy criteria: markedly effective, UA decreased by ≥20%; effective, UA decreased by ≥10%; ineffective, UA decreased

[0038] 1.4 Statistical analysis method SPSS24.0 statistical software was used for data processing. The measurement data (x±s) that conformed to the normal distribution were expressed. The t-test was used for inter-group comparison, and the chi-square test was used for counting data. The difference was considered statistically significant when P < 0.05.

[0039] 2. Results

[0040] 2.1 Comparison of UA and TG levels between the two groups before and after treatment There was no significant difference in UA and TG levels between the two groups before treatment (P>0.05). After treatment, both levels decreased, and the decrease in the treatment group was greater, with a significant difference (P<0.05), as shown in Table 1.

[0041] Table 1 Comparison of Scr, UA and TG levels between the two groups before and after treatment (x±s)

[0042]

[0043] 2.3 Comparison of clinical efficacy between the two groups The effective rate of the treatment group was 98.00%, which was higher than that of the control group (86.00%). The difference was statistically significant (P < 0.05), as shown in Table 3.

[0044] Table 3 Comparison of clinical efficacy between the two groups [cases (%)]

[0045]

[0046] 2.4 Summary and Analysis

[0047] Atherosclerosis is the main factor causing cardiovascular and cerebrovascular diseases, and hyperuricemia will accelerate the occurrence and growth of arteriosclerosis. High concentrations of UA in patients with hyperuricemia participate in inflammatory responses and play a key role in the formation of arteriosclerosis. In addition, elevated UA levels can promote platelet aggregation and lead to thrombosis in the coronary arteries. Therefore, hyperuricemia is associated with many cardiovascular and cerebrovascular diseases, can aggravate arteriosclerosis, and promote the occurrence of cardiovascular and cerebrovascular diseases. The main cause of hyperuricemia is excessive production or insufficient excretion of uric acid in the body, so increasing uric acid excretion is the key to treating the disease.

[0048] Benzbromarone is a uric acid excretion drug that mainly reduces uric acid by inhibiting the reabsorption of uric acid by the proximal renal tubules and promoting the excretion of uric acid by the renal tubules. It can effectively reduce the concentration of uric acid in the blood and has a certain effect on hyperuricemia.

[0049] After oral administration of benzbromarone, the effective rate of the control group reached 86.00%, indicating that benzbromarone has a certain effect on hyperuricemia. However, benzbromarone has toxic side effects such as gastrointestinal reactions.

[0050] After the treatment group was treated with the present invention, the effective rate was as high as 98.00%. It showed that the UA levels of both groups decreased after treatment, and the decrease in the observation group was greater, which suggests that the tea substitute of the present invention can effectively reduce the UA level of patients and is conducive to the recovery of the disease. At the same time, the present invention can directly reduce blood uric acid and has a certain alleviating effect on the increase of creatinine caused by high blood uric acid.

[0051] Related studies have shown that patients with hyperuricemia have abnormal lipid synthesis, especially TG. Hyperuricemia is mostly seen in middle-aged and elderly people, and excessive abdominal fat accumulation leads to insulin resistance, which in turn causes an increase in TG and cholesterol levels. At the same time, since blood lipids are mainly synthesized in the liver, the increase in purines in patients with hyperuricemia will cause an increase in the activity of glucose-6-phosphatase, leading to increased fatty acid synthesis and increased blood lipids. The results of the study showed that there was no significant difference in the TG levels of the two groups before treatment, and both decreased after treatment, and the observation group decreased more, which shows that the present invention can effectively reduce the TG levels of patients.

[0052] In summary, patients with hyperuricemia are very likely to develop cardiovascular and cerebrovascular diseases, and its mechanism needs further study. However, traditional Chinese medicine has mild toxic and side effects in preventing and treating hyperuricemia. The present invention can effectively prevent and treat hyperuricemia, quickly reduce blood uric acid, and at the same time has a certain inhibitory effect on the increase of creatinine caused by hyperuricemia and the intravascular inflammatory reaction caused by hyperuricemia.

[0053] The specific embodiments of the present invention are described in detail above, but they are only examples, and the present invention is not equivalent to the specific embodiments described above. For those skilled in the art, any equivalent modifications and substitutions made to the present invention are also within the scope of the present invention. Therefore, the equalization changes and modifications made without departing from the spirit and scope of the present invention should be included in the scope of the present invention.

Claims

1. A tea substitute for preventing and treating hyperuricemia, characterized in that: The raw materials include the following ingredients: 8-12 parts of Codonopsis pilosula, 8-12 parts of Atractylodes macrocephala, 8-12 parts of Atractylodes lancea, 8-12 parts of Poria or Polyporus, 8-12 parts of Smilax glabra, 8-12 parts of Honeysuckle, 8-12 parts of Trillium, 8-12 parts of Salvia miltiorrhiza, 8-12 parts of Gynostemma pentaphyllum, 4-8 parts of Rhodiola rosea, 4-8 parts of Alismatis orientalis, and 4-8 parts of Licorice.

2. The tea substitute for preventing and treating hyperuricemia according to claim 1, characterized in that: The raw materials include the following ingredients: 10 parts of Codonopsis pilosula, 10 parts of Atractylodes macrocephala, 10 parts of Atractylodes lancea, 10 parts of Poria or Polyporus, 10 parts of Smilax glabra, 10 parts of Honeysuckle, 10 parts of Psoralea corylifolia, 10 parts of Salvia miltiorrhiza, 10 parts of Gynostemma pentaphyllum, 6 parts of Rhodiola rosea, 6 parts of Alismatis orientalis, and 6 parts of Licorice.

3. A method for preparing a tea substitute for preventing and treating hyperuricemia according to claim 1, characterized in that: Mix all the ingredients in proportion and then decoct in water.

Images